On October 28, 2026, two more blood pressure pills were added to FDA's recall records: a combination tablet of telmisartan and amlodipine, and another lot of amlodipine with olmesartan. They join a longer 2026 list that includes Diovan, metoprolol and chlorthalidone. Here's the short answer. Each recall covers specific lots, none of the 2026 entries we found is Class I, and FDA's general advice for Class II and III recalls is that you can keep taking the medicine unless the company or FDA says otherwise.
The lot number is what tells you whether your pill is part of it.
For this guide we read the records themselves in openFDA, FDA's public data service, on November 8, 2026. The records are updated weekly, so treat what follows as a snapshot of that day.
Which blood pressure medicines were recalled in 2026
Every entry below is a voluntary, firm-initiated recall with the status "Ongoing". All but the clonidine records describe nationwide US distribution (the bisoprolol record also lists Puerto Rico); the clonidine records say "Within U.S". Each record lists the affected lot numbers and expiration dates, plus the National Drug Code (NDC). The recalling firm isn't always the name on your bottle, so where a record names a different company, it's in brackets.
Combination pills with amlodipine
- Telmisartan and amlodipine tablets, 40 mg/5 mg, 30-count bottle (manufactured for Mylan Pharmaceuticals Inc.). Firm: Viatris, Inc. Class III. Reason: "Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications." Reported October 28, 2026. Five lots: 3228113, 3228114 and 3228115 (expiring October 31, 2026), and 3228120 and 3228121 (expiring November 30, 2026).
- Amlodipine and olmesartan medoxomil tablets, 30-count bottles (manufactured by Alkem Laboratories Ltd.). Firm: Ascend Laboratories, LLC. Three separate Class II records, one lot each. The 5 mg/40 mg strength (lot 24123460, reported June 10, 2026) and the 10 mg/20 mg strength (lot 25121311, reported July 29, 2026) failed dissolution specifications, with olmesartan medoxomil content below specifications. The 10 mg/40 mg strength (lot 25120696, reported October 28, 2026) is listed as "Out of specification due to dissolution."
Valsartan and ACE inhibitors
- Diovan (valsartan) 160 mg, 90 tablets. Firm: Novartis Pharmaceuticals Corporation. Class II, failed dissolution specifications. Reported August 19, 2026. One lot: AV5913C (expiry 6/2027).
- Ramipril capsules 10 mg, 100- and 500-count bottles. Firm: Hikma Pharmaceuticals USA Inc. (manufactured for Exelan Pharmaceuticals). Class II, failed impurities/degradation specifications (an out-of-specification result for a process impurity, dicyclohexylurea). Reported September 2, 2026.
- Enalapril maleate tablets 20 mg, 1,000-count bottle. Firm: JB Chemicals and Pharmaceuticals Ltd. (distributed by Rising Pharma Holdings). Class II, failed impurities/degradation specifications (an out-of-specification result in the organic impurities test). Reported May 13, 2026.
Beta blockers
- Metoprolol succinate extended-release tablets, 25, 50, 100 and 200 mg. Firm: Teva Pharmaceuticals USA, Inc. Four Class II records, failed dissolution specifications. Reported March 11, 2026.
- Metoprolol succinate extended-release tablets 25 mg, 100-count. Firm: Ascend Laboratories, LLC. Class II, failed dissolution specifications. Reported May 20, 2026.
- Bisoprolol fumarate and hydrochlorothiazide tablets 2.5 mg/6.25 mg, 100-count. Firm: Unichem Pharmaceuticals USA Inc. Class II, for not meeting the N-nitroso bisoprolol impurity specification limits. Reported February 11, 2026.
Diuretics
- Chlorthalidone tablets 25 mg. Firm: Inventia Healthcare Limited (one record names Rising Pharma Holdings as distributor). Two Class II records, failed dissolution specifications. Reported June 24 and September 23, 2026.
- Furosemide tablets 80 mg, 100-count. Firm: Leading Pharma, LLC. Class II, for N-nitroso-furosemide above the recommended intake limit. Reported April 29, 2026.
- Furosemide tablets 40 mg, 1,000-count. Firm: Graviti Pharmaceuticals Private Limited (manufactured for Rising Pharmaceuticals). Class II, presence of a foreign substance. Reported January 28, 2026.
Other blood pressure medicines
- Clonidine transdermal system (a skin patch), 0.1, 0.2 and 0.3 mg/day. Firm: Teva Pharmaceuticals USA, Inc. (made and distributed by Actavis companies). Three Class II records, use of an unapproved raw material. Reported April 15, 2026.
- Prazosin hydrochloride capsules 1, 2 and 5 mg. Firm: Appco Pharma LLC (manufactured for Biocon Pharma). Three Class II records, an N-nitroso-prazosin impurity above acceptable limits. Reported April 8, 2026.
- Doxazosin tablets 4 mg, 1,000-count. Firm: Unichem Pharmaceuticals USA Inc. Class III, tablets imprinted with the wrong ID. Reported February 18, 2026.
Two hospital injections of nicardipine also appear in the 2026 records. They aren't something you'd keep at home, so they're left out here. And if your worry is losartan, lisinopril or irbesartan, a search of 2026 entries for those three returned no matches.
A word on the data itself. The openFDA page for these records says, "Do not rely on openFDA to make decisions regarding medical care." It says the data is updated weekly and that FDA doesn't update a recall's status after it has been classified, so "Ongoing" may be out of date, and the data comes with a note to treat all results as unvalidated. The file we pulled was last updated October 28, 2026. openFDA also says the data shouldn't be used to issue public alerts or to track a recall's lifecycle, and that FDA sometimes corrects a past record, for instance when a firm expands a recall to more lots. Several lots listed here have also passed their expiration dates (three of the five telmisartan and amlodipine lots expired October 31, 2026). So this isn't an alert, and it doesn't mean every lot is still on a pharmacy shelf. It's a starting point for checking your own bottle, with FDA's Enforcement Report and your pharmacist.
What Class I, II and III mean
FDA sorts recalls by how likely the problem is to cause harm. Its definitions:
- Class I: a reasonable probability that using the product will cause serious adverse health consequences or death.
- Class II: use may cause temporary or medically reversible adverse health consequences, or the probability of serious harm is remote.
- Class III: use is not likely to cause adverse health consequences.
FDA's consumer page on drug recalls adds that Class II recalls are generally carried out at the retail level and Class III at the wholesale level.
What "superpotent" and "failed dissolution" mean
Superpotent is the record's word for the Viatris lots: the telmisartan content in those tablets may be above the product's specification, so possibly more drug than each tablet is meant to hold. FDA placed it in Class III, its lowest-risk group.
Failed dissolution specifications is the most common reason on this year's list. A dissolution test is a lab check of how a tablet or capsule releases its drug. FDA's guidance on dissolution testing, written for immediate-release tablets and capsules, explains that absorbing a drug from a tablet depends on the drug being released from it and dissolving, and that these tests are used to assess quality from one lot to the next. A failed result means a lot didn't meet its standard in the lab. The records don't say whether anyone was harmed, and they don't say why a lot failed.
Three entries (bisoprolol with hydrochlorothiazide, prazosin and the 80 mg furosemide) involve N-nitroso impurities; the prazosin record calls its impurity a nitrosamine drug substance-related impurity. FDA's nitrosamine page says these impurities may increase the risk of cancer with exposure above acceptable levels over long periods, and that patients taking prescription medicines with potential nitrosamine impurities "should not stop taking their medications."
The valsartan, losartan and irbesartan recalls of 2018 and 2019
If "blood pressure recall" sounds familiar, this is probably why. On July 13, 2018, FDA announced a recall of certain batches of valsartan because of an impurity called N-nitrosodimethylamine (NDMA). Recalls of some irbesartan (for NDEA) and losartan (first for NDEA, later for NMBA) followed. FDA scientists estimated that if 8,000 people took the highest valsartan dose (320 mg) from the recalled batches daily for four years, there might be one additional case of cancer over the lifetimes of all 8,000.
Through all of it, FDA's message to patients stayed the same: continue taking the current medicine until the pharmacist provides a replacement or the doctor prescribes a different medicine for the same condition. Its reason was blunt. Untreated high blood pressure raises the risk of heart attacks and stroke.
How to check your own pill
- Find the drug name, strength and maker on your bottle or pharmacy label. During the valsartan recalls, FDA told patients to compare the company, National Drug Code and lot number on the prescription bottle with the recall list.
- Check the lot number. FDA's consumer page says to compare the lot number on your medicine's label with the lot number in the recall notice. Each recall above covers only the lots its record listed when we checked.
- Search the FDA Enforcement Report for your drug's name. FDA says every recall it monitors goes into this report once classified. The FDA recalls page is narrower: it collects press releases and public notices, and FDA notes that not all recalls are posted there.
- Ask your pharmacist if the details are missing or don't match neatly. Several entries are 1,000-tablet bottles, so the label on your own bottle may not look like the record. FDA notes that pharmacists may be able to dispense the same medicine from a lot that hasn't been recalled.
- Sign up for alerts if you want them. The Enforcement Report has an email service that can notify you of new recalls by keyword, such as a drug name.
Why not to stop on your own
FDA's consumer page says that for Class II and III recalls, consumers can generally continue taking the medicine unless the recalling company provides other instructions, and that "in some instances, stopping your medicine may be more harmful to your health than continuing to take the recalled medicine."
So if your lot matches, the next step is a phone call, not a decision made at the kitchen counter. Your pharmacist or doctor can tell you whether anything needs to change, and what to do with the bottle you have.
One exception has nothing to do with recalls. The Diovan and Cozaar labels carry a boxed warning that drugs acting on the renin-angiotensin system can cause injury and death to the developing fetus. If you are pregnant or could become pregnant, talk to your doctor now, recall or not.
Mention your supplements too
When you make that call, mention what else you take. The Diovan label says potassium supplements or salt substitutes may lead to increases in blood potassium (more in valsartan and potassium). The Cozaar label tells prescribers to advise patients not to use potassium supplements or potassium-containing salt substitutes without consulting their healthcare provider (see losartan and potassium). If you keep your list in Pilora, its interaction checker covers pairs like these.
The bottom line
This year's blood pressure recalls are lot-specific, and every one I found is Class II or III. I think that makes them a reason to check a number on a label, not a reason to stop a medicine. If your lot matches, or you can't tell, call your pharmacist or doctor before you change anything, and have the bottle in your hand when you do.
